欢迎来到 CSNpharm! 产品仅用于科研!
首页 400-920-2911

c-Met/HGFR

c-Met/HGFR

货号 产品名 CAS号 信息
CSN17399 Tyrosine Kinase Inhibitor 1021950-26-4 Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma.
CSN12917 Tivantinib 905854-02-6 Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM with little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.
CSN16106 SGX-523 1022150-57-7 SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM.
CSN17517 SCR-1481B1 1174161-86-4 SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
CSN17684 Savolitinib 1313725-88-0 Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50= 5 nM) with potential antineoplastic activity.
CSN20348 SAR125844 1116743-46-4 SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity.
CSN19153 S49076 1265965-22-7 S49076 is a potent inhibitor of MET, AXL/MER, and FGFRs.
CSN12934 PHA-665752 477575-56-7 PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.
CSN18635 PF-04217903 Methanesulfonate 956906-93-7 PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 4.8 nM.
CSN16129 PF-04217903 956905-27-4 PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).
CSN17159 NVP-BVU972 1185763-69-2 NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects.
CSN23685 Ningetinib Tosylate   1394820-77-9 Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively.
CSN17658 MK-8033 HCl 1283000-43-0 MK8033 hydrochloride is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN13613 MK-8033 1001917-37-8 MK-8033 is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN16566 MK-2461 917879-39-1 MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 0.4-2.5 nM, also inhibits FGFR1/2/3, KDR, TrkA/B, and Flt4 with IC50 of 65/39/50 nM, 44 nM, 46/61 nM, and 78 nM respectively.
CSN13734 LY2801653 1206799-15-6 LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM.
CSN17560 LY2801653 2HCl 1206801-37-7 LY2801653 dihydrochloride is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM).
CSN22436 JNJ-38877618 943540-74-7 JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
CSN12936 JNJ-38877605 943540-75-8 JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.
CSN15776 INC28060 1029712-80-8 INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
CSN15829 Golvatinib 928037-13-2 Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM.
CSN24153 Glumetinib 1642581-63-2 Glumetinib is a novel, potent and highly selective inhibitor of c-Met.
CSN17479 Glesatinib HCl 1123838-51-6 Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
CSN12685 Foretinib 849217-64-7 Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and with little activity to FGFR1 and EGFR.
CSN15875 Tepotinib   1100598-32-0 EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, > 200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
CSN24316 Dihexa Acetate N/A Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.
CSN22378 c-Met-IN-2 1635406-73-3 c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
CSN16262 c-Met Inhibitor 1 1357072-61-7 c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
CSN16525 BMS-794833 1174046-72-0 BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 1.7 and 15 nM.
CSN13471 BMS-777607   1025720-94-8 BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, being 40-fold selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
CSN17199 AMG-458 913376-83-7 AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
CSN17516 AMG-337 1173699-31-4 AMG-337 is a potent, highly selective and ATP-competitive MET kinase inhibitor with an IC50 of < 5nM in enzymatic assays.
CSN16548 AMG-208 1002304-34-8 AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM.
CSN16259 Altiratinib 1345847-93-9 Altiratinib is a c-MET/TIE-2/VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
CSN23572 Norcantharidin 29745-04-8
<< PREV 1 2 NEXT >>